INTRODUCTION
An essential step in neurotransmission is the influx of Ca 2 þ through voltage-gated calcium channels. These voltage-dependent calcium channels have been described to be associated with epilepsy and several neuropsychiatric disorders such as autism and schizophrenia. [1] [2] [3] Typically, these channels are composed of four subunits: an alpha1, alpha2-delta, beta and gamma subunit, each encoded by several genes. The a 1 subunit is the primary subunit necessary for channel functioning and in total 10 genes are known to encode this subunit. The a 2 d subunit consists of two peptides, the alpha2 and the delta peptide. They are posttranslationally cleaved and subsequently linked by disulfide bonds. Four genes are known to encode these subunits (CACNA2D1, CACNA2D2, CACNA2D3 and CACNA2D4). 4 Co-expression of the a 2 d genes enhances the level of expression of the a 1 subunit and causes an increase in current amplitude. The beta subunit has a major role in stabilizing the final a 1 subunit conformation and delivering it to the cell membrane. 4 Interestingly, the a 2 d subunits encoded by CACNA2D1 and CACNA2D2 are targets for gabapentinoid drugs, pregabalin and gabapentin, two anti-epileptic drugs. 5 Mice bearing point mutations in the CACNA2D1 gene have a decreased response to pregabalin as well as an abnormal central nervous system synaptic transmission. 6 Furthermore, the a 2 d subunit encoded by the CACNA2D1 gene is widely expressed in the nervous system, especially in neuronal cell types. 7 This suggests a potential role for CACNA2D1 in the pathogenesis of epilepsy.
Here we report on three patients with epilepsy and intellectual disability (ID) with a genomic aberration affecting the CACNA2D1 gene, pinpointing this gene as an interesting candidate gene for epilepsy and ID.
MATERIALS AND METHODS

Clinical reports
Patient 1 (Belgium). Patient 1 is the fifth child of healthy non-consanguineous parents. Family history is negative for epilepsy or other developmental problems. She was born at term in breech position after an uneventful pregnancy. Birth weight (3 kg), height (48 cm) and head circumference were normal. At the age of 1 year, a global developmental delay was diagnosed and physiotherapy was started. The first epileptic seizures occurred at the age of 3 years and were characterized by twitching of the face and the left arm. She also had generalized tonic-clonic seizures with loss of consciousness and urine loss. EEGs at that time showed multifocal spikes and spike complexes mainly in the right hemisphere. Later she also developed shocks and atonic seizures. Although several drugs were tested, daily epileptic seizures persisted. MRI of the brain revealed bilateral frontotemporal polymicrogyria, mega cisterna magna and a cyst in the cavum veli interpositi, under the splenium of the corpus callosum expanding posterior to the supravermian cistern.
At the age of 15 years, she is not able to speak in sentences and has difficulties walking long distances. IQ testing revealed an overall IQ around 50. Upon clinical examination at this age, her height is 150 cm (oP5), weight 57 kg (P75) and head circumference 54.5 cm (P50). Besides the psychomotor difficulties, she still suffers from epilepsy for which she is now treated with topiramate, valproic acid, lamotrigine, oxcarbazepine and clobazam. The last EEG was abnormal with multifocal epileptic activity.
Patient 2 (Belgium, DECIPHER patient 285588). Patient 2 is the second child of healthy non-consanguineous parents. She was born at term after an uneventful pregnancy. Birth weight (3,8 kg) , length (50 cm) and head circumference (33,5 cm) were normal. Initial neuromotor development appeared near normal with independent sitting at the age of 9 months and walking at 18 months. At the age of 15 months, she experienced a first generalized tonic-clonic seizure during a febrile episode. MRI of the brain was normal, EEG showed slowing over the left parasaggital leads but no epileptic abnormalities. Despite treatment with valproic acid, she continued to experience seizures between the ages of 21 months and 6 years. These seizures were characterized by generalized tonic contraction of limbs and trunk, revulsion of the eyes and loss of consciousness, and sometimes necessitated intubation. After one such seizure, a transient postictal paresis of the right arm and leg was observed, suggesting the possibility of a focal onset in the left hemisphere. MRI at the age of 3 years showed global cortical atrophy. From the age of 7 years, she became seizure-free under valproic acid treatment. After the first epileptic seizure, a delayed psychomotor development was noticed. Every subsequent seizure also resulted in a slight regression in psychomotor development. In addition, gait ataxia was noted on clinical exam from the age of 36 months. Her IQ is estimated around 80 and she followed special education. Clinical examination shows some craniofacial dysmorphic features with hypertelorism and striking blue irises. Inspection of the skin shows multiple ephelides spread throughout the body, mostly pronounced in the face, neck and upper limbs. There are no café-au-lait spots nor cutaneous neurofibromes. There is lymphedema of the left foot, as a result of a surgical procedure at the age of 10 years for lymphangitis. She is still relatively obese (BMI ¼ 25, among healthy diet) and has a short stature (length P10). Head circumference is at the 75th percentile. From 11 to 15 years she has had transient diabetes with hyperinsulinemia, which disappeared under diet.
Patient 3 (France, DECIPHER patient 259199). Patient 3 was born at term to non-consanguineous parents. Her developmental milestones were significantly delayed; speech delay was noticed and she was only able to walk at the age of 3 years. Although she follows special education, at the age of 16 years, she is still not able to read or write. Generalized epileptic seizures first occurred at the age of 5 years. The EEG showed frontotemporal spikes, brain MRI did not reveal any abnormalities. Treatment with lamotrigine was initiated, and valproic acid was subsequently associated. Under this treatment, the EEG normalized but she continued to suffer from rare epileptic seizures (one/year).
Clinical examination at the age of 16 years reveals facial dysmorphism with synophris, short nose, open mouth, everted lower lip, thick lips and low set ears. Clinodactyly V, brachymetacarpy and -tarsy V are also observed. Weight (55.8 kg), height (1.66 m) and head circumference (54 cm) are normal at this age.
Cytogenetic analyses
Analysis of G-banded metaphase chromosomes from patient 1 and her parents was performed on short-term lymphocyte cultures using standard procedures. Fluorescence in situ hybridization (FISH) was performed as previously described. 8 FISH probes were selected from the 1 Mb and 32 K set clones via the Ensembl Genome Browser website (http://www.ensembl.org/). Table 1 shows the FISH probes that were used in the FISH experiments.
Array CGH DNA was isolated from total blood using the QiaAmp Purification Kit (Qiagen, Venlo, The Netherlands) according to the manufacturer's instructions. DNA was hybridized on the Agilent Human Genome CGH Microarray 180 K (AMADID#014950, Agilent Technologies, Diegem, Belgium), according to the manufacturer's instructions with minor modifications. 9 Array CGH data were analyzed with arrayCGHbase 10 for copy number analysis.
X-inactivation assay
Examination of the methylation pattern at the androgen receptor (AR) locus was performed on genomic DNA isolated from blood leucocytes according to Allen et al. 11 
RNA isolation
Epstein-Barr virus-transformed B-lymphocyte cell lines were derived from patient 1 and five age-and sex-matched controls. These cell lines were grown in standard conditions. RNA was isolated using the miRNeasy kit (Qiagen, Venlo, the Netherlands) according to the manufacturer's instructions.
Quantitative PCR
cDNA synthesis was performed on 2 mg total RNA with 4 ml of iScript reaction mix and 1 ml of iScript reverse transcriptase (iScript, Bio-Rad, Nazareth, Belgium) in a final volume of 20 ml. This mix was then incubated for 5 0 at 25 1C, 30 0 at 42 1C and 5 0 at 85 1C using the iCycler (Bio-Rad). qPCR was performed with 5 ng cDNA, 2.5 ml of ssoAdvanced mastermix (Bio-Rad) and 5 mM primers in a total volume of 5 ml. Normalization of expression levels was done against three reference genes TBP, UBC and HPRT1. Analysis was performed using the qBasePlus software (http://www.biogazelle.com). Primer sequences are available on request.
RESULTS
Patient 1
Conventional karyotyping revealed a de novo apparently balanced reciprocal translocation 46,X,t(X;7)(p10;q21.2) in patient 1 (Figure 1a) . The translocation breakpoints were further mapped using FISH. BAC-probes RP11-556B13 and RP11-560N24 directly flank the breakpoint on chromosome 7 (Figure 1b) . On the X-chromosome, the breakpoint resides in the centromeric region, demonstrated by the split signal of the centromeric probe (Figure 1c) , whereas on chromosome 7 the CACNA2D1 gene is disrupted (Figure 2 ). Molecular karyotyping did not reveal any aberrations near the breakpoint regions for patient 1 or any other causal CNVs.
The X-inactivation assay revealed a total (100:0) skewing of the X-chromosome inactivation.
Expression analysis of the ARHGEF9 gene, located close to the breakpoint on chromosome X, was performed in patient 1 and five sex-and age-matched controls. No significant difference was observed (Figure 2 ). This deletion was inherited from the mother who presents with mild ID and speech delay. She is also illiterate. The data of all three patients were submitted to ClinVar (http:// www.ncbi.nlm.nih.gov/clinvar/, accession numbers SCV000165997-SCV000165999).
DISCUSSION
We describe here three patients with epilepsy and ID. In patient 1, the t(X;7) translocation breakpoint on chromosome 7 disrupts the CACNA2D1 gene. In patient 2 and 3, the smallest region of overlap shared by the deletions contains only five genes (HGF, CACNA2D1, PCLO, SEMA3E, SEMA3A), including the CACNA2D1 gene. These data suggest that disruption or deletion of CACNA2D1 is very likely to be associated with the epilepsy observed in these patients.
In patient 1, the epilepsy is associated with polymicrogyria, which is not observed in patients 2 and 3, or was this noted in two patients with overlapping deletions previously reported by Mefford et al. 12 These two patients, respectively, present with myoclonic astatic epilepsy and symptomatic generalized epilepsy. All three patients reported here suffer from generalized epileptic seizures. In patient 1 focal motor, generalized tonic-clonic, atonic and myoclonic seizures were observed, suggesting multifocal or symptomatic generalized epilepsy. Patient 2 presents with generalized tonic(-clonic) seizures. In this patient, there is limited evidence for focal onset of the seizures. The age at seizure onset ranged from 21 months in patient 2 to 3 and 5 years of age in patient 1 and 3. In the patients from Mefford et al, seizure onset was observed at 2 months of age (patient T438) and 9 months (patient T964).
In patient T438 with myoclonic astatic epilepsy, the deletion segregated in the family with a spectrum of epilepsy and cognitive phenotypes. The deletion in patient 3 was inherited from the mother who presents with mild ID but no epilepsy. The maternal grandfather also presented with mild ID and a maternal aunt with ID and epilepsy. Unfortunately, both could not be assessed for further testing. The aberration in patient 1 and 2 occurred de novo.
The breakpoint on the X-chromosome in patient 1 resides in the centromeric region. The ARHGEF9 gene, of which deletion has been described in patients with epilepsy and ID, [13] [14] [15] is located close to the breakpoint. To evaluate whether this gene might contribute to the more severe phenotype observed in patient 1, both X-inactivation as well as expression of ARHGEF9 were evaluated for this patient. ARHGEF9 is still expressed in this patient (Supplementary Figure 1) and total X-skewing was observed in favor of the abnormal X-chromosome.
Although in our control cohort of approximately 5000 cases not one aberration in the CACNA2D1 gene could be detected, the database of genomic variants (http://projects.tcag.ca/variation/) contains three studies [16] [17] [18] describing deletions comprising coding regions of CACNA2D1 in healthy individuals.
All of this suggests a broader spectrum of clinical phenotypes observed with CACNA2D1 aberrations.
Epilepsy was treated in patients 2 and 3 with valproic acid, which causes an increased concentration of gamma-aminobutyric acid in central nervous system synapses and blocks voltage-gated sodium channels and T-type calcium channels. 19 Malformations of cortical development, including polymicrogyria, are an important cause of therapy-resistant epilepsy. 20, 21 In patient 1, epilepsy is associated with polymicrogyria, which might explain the therapy resistant nature of the observed epilepsy in this patient.
Recently, mutations in the CACNA2D2 gene, which encodes another peptide of the a 2 d subunit, have been associated with epilepsy. 22, 23 Mutations in the other isoforms have been linked to disorders such as Brugada syndrome, short QT syndrome (CACNA2D1), autosomal recessive cone dystrophy and night blindness (CACNA2D3) and autism spectrum disorders (CACNA2D4). [24] [25] [26] [27] [28] Deletion of the CACNA2D4 gene has been described in patients with bipolar disorder. 29 Cardiac defects linked to Brugada syndrome and short QT syndrome associated with loss-of-function of CACNA2D1 were not observed in the patients reported here.
Besides epilepsy, all three patients also present with ID. Although haploinsufficiency of the CACNA2D1 gene could account for this, in patients 2 and 3, other genes in the deletion interval are likely to contribute to the observed phenotype. The PCLO gene and a group of semaphorin genes are located in the common deleted interval in patients 2 and 3 ( Figure 2) . PCLO encodes the piccolo presynaptic cytomatrix protein, which is involved in monoaminergic neurotransmission 30 and synaptic vesicle exocytosis 31 and has already been associated with major depression disorder. 32 The semaphorins have an important role in the development of the nervous system and in axonal guidance. 33 A missense mutation in the SEMA3E gene has been described in a single patient with CHARGE Syndrome. 34 The typical features associated with CHARGE Syndrome such as coloboma of the eye, heart defects and deafness were, however, not observed in patients 2 and 3. In patient 2, deletion of the GRM3 gene encoding the metabotropic glutamate receptor 3 protein could also contribute to the ID. This protein is involved in learning, memory, anxiety and the perception of pain. 35 The obesity with hyperinsulinism in patient 2 is very likely to be caused by deletion of the CD36 gene (Figure 2 ). This gene encodes a glycoprotein of the platelet surface and may function in the transport and/or as a regulator of fatty acid transport. 36 In mice, deletion of the CD36 gene was found to be responsible for insulin resistance, defective fatty acid metabolism and hypertriglyceridemia. 37 In humans, deficiency in CD36 is associated with insulin resistance in the Japanese population. 38 To conclude, we report three new patients with epilepsy and ID in whom the CACNA2D1 gene is disrupted or deleted and as such is a candidate gene for the epileptic phenotype. In addition, in patient 2, the obesity with hyperinsulinism could be explained by the deletion of the CD36 gene.
Comprehensive studies will, however, be needed to further unravel the genotype-phenotype correlation associated with aberrations of the CACNA2D1 gene.
